{"id":"W2026940417","doi":"10.1007/s10637-014-0139-9","title":"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Oncology; Maximum tolerated dose; Internal medicine; Pharmacology; Chemotherapy; Cisplatin; Cancer; Gefitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001032825,0.0001629499,0.0003545774,0.0001479761,0.00004578793,0.00001305125,0.00003814241,0.00004148117,0.00002473622],"category_scores_gemma":[0.0001396522,0.0001185409,0.00002637133,0.0002941434,0.0001548416,0.0001772568,0.00001067098,0.0000896093,0.00000199148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006668798,"about_ca_system_score_gemma":0.0003916533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001013081,"about_ca_topic_score_gemma":0.00003974959,"domain_scores_codex":[0.9987903,0.00004380328,0.0003592964,0.0002501177,0.0004051492,0.0001513401],"domain_scores_gemma":[0.9990942,0.0001251588,0.0002429636,0.0001503586,0.0001940515,0.0001932563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2326647,0.009815691,0.619086,0.0003274711,0.0007427132,0.00001763728,0.007818139,0.001481861,0.002120667,0.006244914,0.000883728,0.1187965],"study_design_scores_gemma":[0.4623598,0.01282321,0.5202831,0.0004723674,0.0002214408,0.000002325588,0.0001218243,0.001046421,0.0009740773,0.001318224,0.0001706473,0.0002065985],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967986,0.00001672412,0.0001083191,0.0008771158,0.00005288663,0.00130867,0.00002380056,0.00002564329,0.000788255],"genre_scores_gemma":[0.9949824,0.000001826603,0.003849551,0.00026447,0.00006324477,0.00007253327,0.0004912412,0.00002160617,0.0002531875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2296951,"threshold_uncertainty_score":0.4833957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008347684921314954,"score_gpt":0.287026971593901,"score_spread":0.2786792866725861,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}